Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO).

Authors :: Quinquenel A
Aurran-Schleinitz T
Clavert A
Cymbalista F
Dartigeas C
Davi F
de Guibert S
Delmer A
Dilhuydy MS
Feugier P
Fornecker LM
Ghez D
Guieze R
Laribi K
Leblond V
Leprêtre S
Letestu R
Lévy V
Nguyen-Khac F
Michallet AS
Tomowiak C
Tournilhac O
Ysebaert L
Troussard X
Source :: HemaSphere [Hemasphere] 2020 Sep 23; Vol. 4 (5), pp. e473. Date of Electronic Publication: 2020 Sep 23 (Print Publication: 2020).
Publication Year :: 2020
Abstract: As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome.<br /> (Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)

Full Text Access

Tools